Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Gastro-Enteropancreatic Neuroendocrine Tumor”

88 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 88 results

Testing effectiveness (Phase 2)Active Not RecruitingNCT01841736
What this trial is testing

Pazopanib Hydrochloride in Treating Patients With Progressive Carcinoid Tumors

Who this might be right for
Foregut Neuroendocrine TumorHindgut Neuroendocrine TumorMetastatic Digestive System Neuroendocrine Tumor G1+5 more
National Cancer Institute (NCI) 171
Testing effectiveness (Phase 2)Looking for participantsNCT06427798
What this trial is testing

Somatostatin-Receptors (SSTR)-Agonist [212Pb]VMT-alpha-NET in Metastatic or Inoperable SSTR+ Gastrointestinal Neuroendocrine Tumor and Pheochromocytoma/Paraganglioma Previously Treated With Systemic Targeted Radioligand Therapy

Who this might be right for
Somatostatin Receptor PositiveGastrointestinal Neuroendocrine TumorsPheochromocytoma+1 more
National Cancer Institute (NCI) 66
Testing effectiveness (Phase 2)Ended earlyNCT02736448
What this trial is testing

177Lutethium - Peptide Receptor Radionuclide Therapy (Lu-PRRT) Plus Capecitabine Versus Lu-PRRT in FDG Positive, Gastro-entero-pancreatic Neuroendocrine Tumors

Who this might be right for
Gastro-entero-pancreatic Neuroendocrine Tumors
Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS 35
Testing effectiveness (Phase 2)UnknownNCT03457844
What this trial is testing

Anlotinib in Patients With Gastroenteropancreatic Neuroendocrine Tumor G3

Who this might be right for
Gastroenteropancreatic Neuroendocrine Tumor G3
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. 60
Testing effectiveness (Phase 2)Study completedNCT01010126
What this trial is testing

Temsirolimus and Bevacizumab in Treating Patients With Advanced Endometrial, Ovarian, Liver, Carcinoid, or Islet Cell Cancer

Who this might be right for
Adult Hepatocellular CarcinomaAdvanced Adult Hepatocellular CarcinomaEndometrial Serous Adenocarcinoma+42 more
National Cancer Institute (NCI) 252
Testing effectiveness (Phase 2)Study completedNCT02611024
What this trial is testing

Pharmacokinetic Study of Lurbinectedin in Combination With Irinotecan in Patients With Selected Solid Tumors

Who this might be right for
Advanced Solid TumorsGlioblastomaSoft Tissue Sarcoma (Excluding GIST)+9 more
PharmaMar 316
Very early researchActive Not RecruitingNCT04993261
What this trial is testing

An Investigational Scan (Dual Energy CT) in Detecting Gastrointestinal Carcinoid Tumors

Who this might be right for
Carcinoid SyndromeCarcinoid TumorDigestive System Neuroendocrine Tumor G1+1 more
M.D. Anderson Cancer Center 71
Early research (Phase 1)Study completedNCT01263353
What this trial is testing

Safety and Tolerability of Pasireotide LAR in Combination With Everolimus in Advanced Metastatic NETs

Who this might be right for
Gastroenteropancreatic Neuroendocrine Tumor of the Pulmonary ot Gastroenteropancreatic System
Novartis Pharmaceuticals 36
Testing effectiveness (Phase 2)Active Not RecruitingNCT03600233
What this trial is testing

Study of CVM-1118 for Patients With Advanced Neuroendocrine Tumors

Who this might be right for
Neuroendocrine TumorsPancreatic Neuroendocrine TumorGastro-enteropancreatic Neuroendocrine Tumor+2 more
TaiRx, Inc. 34
Testing effectiveness (Phase 2)Ended earlyNCT05987176
What this trial is testing

Comparison of Adjuvant Treatment With 177Lu-DOTATATE to Best Supportive Care in Patients After Resection of Neuroendocrine Liver Metastases

Who this might be right for
Neuroendocrine Tumor G1 (NET G1)/CarcinoidNeuroendocrine Tumor Grade 2Neuroendocrine Tumors+3 more
Imperial College London 1
Not applicableStudy completedNCT03017690
What this trial is testing

Lanreotide and Octreotide Long Acting Release (LAR) for Patients With Advanced Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs)

Who this might be right for
Gastroenteropancreatic Neuroendocrine Tumor
Ipsen 22
Not applicableStudy completedNCT03288402
What this trial is testing

Investigation of the Effects of Diet on the Measurement of Plasma Chromogranin in NET Patients

Who this might be right for
Neuroendocrine Tumors
University Hospitals Coventry and Warwickshire NHS Trust 346
Not applicableStudy completedNCT01476592
What this trial is testing

A Biological Study of Resveratrol's Effects on Notch-1 Signaling in Subjects With Low Grade Gastrointestinal Tumors

Who this might be right for
Neuroendocrine Tumor
University of Wisconsin, Madison 7
Not applicableUnknownNCT03863106
What this trial is testing

The Lyon Real World Evidence in Metastatic NeuroEndocrine Tumours

Who this might be right for
Gastro-enteropancreatic Neuroendocrine TumorHealth Care CostsMetastatic Cancer
Hospices Civils de Lyon 880
Not applicableLooking for participantsNCT05196087
What this trial is testing

Non-Invasive Artificial Intelligence-Based Platform MonIToring Program (NIP IT!)

Who this might be right for
Breast CancerMelanomaGastrointestinal Neuroendocrine Tumor
University Health Network, Toronto 500
Testing effectiveness (Phase 2)Study completedNCT03980925
What this trial is testing

Platinum-doublet Chemotherapy and Nivolumab for the Treatment of Subjects With Neuroendocrine Neoplasms (NENs) of the Gastroenteropancreatic (GEP) Tract or of Unknown (UK) Origin.

Who this might be right for
Neuroendocrine TumorsNeuroendocrine NeoplasmGastroenteropancreatic Neuroendocrine Tumor
Grupo Espanol de Tumores Neuroendocrinos 37
Testing effectiveness (Phase 2)WithdrawnNCT04276597
What this trial is testing

Phase-II Study of Lu177DOTATOC in Adults With STTR(+)Pulmonary, Pheochromocytoma, Paraganglioma, Unknown Primary, Thymus NETs (PUTNET), or Any Other Non-.GEP-NET.

Who this might be right for
Pulmonary Neuroendocrine NeoplasmPheochromocytomaParaganglioma+7 more
Excel Diagnostics and Nuclear Oncology Center
Not applicableStudy completedNCT04946305
What this trial is testing

A Post Marketing Surveillance on Lutathera® in Patients With Somatostatin Receptor Positive Gastroenteropancreatic Neuroendocrine Tumor in Korea

Who this might be right for
Somatostatin Receptor-positive GEP-NET
Novartis Pharmaceuticals 89
Large-scale testing (Phase 3)Study completedNCT04852679
What this trial is testing

Study to Assess the Efficacy and Safety of Lanreotide Autogel® in Chinese Participants With GEP-NETs

Who this might be right for
Gastroenteropancreatic Neuroendocrine Tumor
Ipsen 43
Testing effectiveness (Phase 2)WithdrawnNCT04614766
What this trial is testing

A Clinical Trial Evaluating the Safety of Combining Lutathera(R) and Azedra(R) to Treat Mid-gut Neuroendocrine Tumors

Who this might be right for
Gastro-enteropancreatic Neuroendocrine TumorNeuroendocrine Tumors
David Bushnell
Load More Results